1. Home
  2. DNLI vs EXTR Comparison

DNLI vs EXTR Comparison

Compare DNLI & EXTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DNLI
  • EXTR
  • Stock Information
  • Founded
  • DNLI 2013
  • EXTR 1996
  • Country
  • DNLI United States
  • EXTR United States
  • Employees
  • DNLI N/A
  • EXTR N/A
  • Industry
  • DNLI Biotechnology: Biological Products (No Diagnostic Substances)
  • EXTR Telecommunications Equipment
  • Sector
  • DNLI Health Care
  • EXTR Telecommunications
  • Exchange
  • DNLI Nasdaq
  • EXTR Nasdaq
  • Market Cap
  • DNLI 2.1B
  • EXTR 2.4B
  • IPO Year
  • DNLI 2017
  • EXTR 1999
  • Fundamental
  • Price
  • DNLI $14.46
  • EXTR $19.75
  • Analyst Decision
  • DNLI Strong Buy
  • EXTR Strong Buy
  • Analyst Count
  • DNLI 15
  • EXTR 6
  • Target Price
  • DNLI $33.85
  • EXTR $21.42
  • AVG Volume (30 Days)
  • DNLI 1.7M
  • EXTR 1.3M
  • Earning Date
  • DNLI 08-11-2025
  • EXTR 08-06-2025
  • Dividend Yield
  • DNLI N/A
  • EXTR N/A
  • EPS Growth
  • DNLI N/A
  • EXTR N/A
  • EPS
  • DNLI N/A
  • EXTR N/A
  • Revenue
  • DNLI N/A
  • EXTR $1,140,067,000.00
  • Revenue This Year
  • DNLI N/A
  • EXTR $9.29
  • Revenue Next Year
  • DNLI $323.34
  • EXTR $8.03
  • P/E Ratio
  • DNLI N/A
  • EXTR N/A
  • Revenue Growth
  • DNLI N/A
  • EXTR 2.05
  • 52 Week Low
  • DNLI $10.57
  • EXTR $10.10
  • 52 Week High
  • DNLI $33.33
  • EXTR $21.35
  • Technical
  • Relative Strength Index (RSI)
  • DNLI 53.04
  • EXTR 60.76
  • Support Level
  • DNLI $12.92
  • EXTR $16.85
  • Resistance Level
  • DNLI $15.06
  • EXTR $21.15
  • Average True Range (ATR)
  • DNLI 0.78
  • EXTR 0.85
  • MACD
  • DNLI 0.06
  • EXTR 0.20
  • Stochastic Oscillator
  • DNLI 72.03
  • EXTR 64.44

About DNLI Denali Therapeutics Inc.

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.

About EXTR Extreme Networks Inc.

Extreme Networks Inc provides cloud networking solutions and industry services and support. Extreme designs, develops, and manufactures wired, wireless, and software-defined wide area-network (SD- WAN) infrastructure equipment, software and cloud-based network management solutions. The company's cloud solution is a single platform that offers unified network management of wireless access points, switches, and SD-WAN. The company operates in a single segment which develops and markets network infrastructure equipment. Roughly half of the firm's revenue is generated in the Americas, with the rest coming from Europe, the Middle East, Africa, and Asia-Pacific.

Share on Social Networks: